Monoclonal Antibodies
Research from K. Vanbesien and co-authors in the area of monoclonal antibodies published
Published in Drug Week, June 19th, 2009
According to recent research from the United States, "The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality (TRM), relapse, overall survival (OS), and disease-free survival (DSF) in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) undergoing reduced intensity conditioning (RIC). We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan (Flu + Mel) + alemtuzumab conditioning and 59 patients treated at the M.D."
"Anderson Cancer Center with Flu + Mel conditioning. Both groups had similar patient and donor characteristics. There were no significant...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2009-06-19)
More Articles from Drug Week
- American Academy of Otolaryngology -- Head and Neck Surgery
ENT Society releases novel clinical practice guideline manual - American College of Chest Physicians
News briefs from the June issue of CHEST - American Society for Radiation Oncology
External beam partial breast irradiation most cost-effective treatment - American Society of Plastic Surgeons
Surgery in patients with RA is often 'too little, too late' - BioMed Central
'Shock and kill' research gives new hope for HIV-1 eradication - Elsevier Health Sciences
Hispanic children in US at greater risk for obesity than other ethnic/racial groups - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
